新疆医科大学学报

参考文献

[1]孙海旭,王枫,张普一,等.卵巢储备功能监测研究进展与卵巢早衰预测[J].国外医学计划生育分册,2005,24(5):259.

[2]Shamilova NN,Marchenko LA,Dolgushina NV,et al.The role of genetie and autoimmune factors in premature ovarian failure[J].J Assist Reprod Genet,2013,30(5):617-622.

[3]Santom N.Mechanisms ofpremature ovarian failure[J].Ann Endocrinol(Paris),2003,64(2):87-92,

[4]Russell P.The clinicpathological premature ovarian failure[J].Verh Dtsch Ges Pathol,1997,81(6):197-200.

[5]Loutradis D,Drakakis P,Milingos S,et al.Alternative approaches in the management of poor response in controlled ovarian hyperstimulation(COH)[J].Ann N Y Acad Sci,2003,997:112-119.

[6]Kyrou D,Kolibianakis EM,Venetis CA,et al.How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization:a systemic review and meta-analysis[J].Fertil Stefil,2009,91:749-769.

[7]Hill MJ,McWilliams GDE,Miller KA,et al.A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates[J].Fertil Steril,2009,91:739-743.

[8]Palomba S,Falbo A,Del-Negro S,et al.Use of oral contraceptives in infertile patients:A descriptive review[J].Reprod Biomed Online,2006,22:537-546.

[9]Huirne JA,Van Loenen AC,Donnez J,et al.Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist:a randomized study[J].Reprod Biomed Online,2006,13(2):235-245.

[10]Chung-Hoon Kim,Rae-Mi You,Hyuk-Jae Kang,et al.GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI[J].Clin Exp Reprod Med,2011,8(4):228-233.

[11]Rombauts L,Healy D,Norman RJ.A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients[J].Hum Reprod,2006,21(1):95-103.

[12]Badawy A,Elnashar A,E-l Ashry M,et al.Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage:prospective randomized study[J].Fertil Steril,2009,91(3):694-697.

[13]Casson PR,Santoro N,Elkind-Hirsch K,et al.Postmenopausal dehydroepiandmsterone administration increases free insulinllke growth factor-I and decreases high-density lipoprotein:a six-month trial[J].Fenil Steril,1998,70(1):107.

[14]Haning RV Jr,Hackett RJ,Flood CA,et al.Plasma dehydroepiandrosterone sulfate serves as a prehomone for 48%of follicular fluid testosterone during treatment withmenotropins[J].J Clin Endocrinol Metab,1993,76(5):1301.

[15]Anderson E,Lee GY,O’Brien K.Polycystic ovarian condition in the dehydroepiandrosterone-treated rat mode1:hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles[J].Anat Rec,1997,249(1):44.

[16]Lainas TG,Sfontouris IA.Zorzovilis IZ,et al.Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystie ovary syndrome treated for IVF:aprospective randomized controlled trial(RCT).Hum Reprod,2010,25:683-689.

[17]Gleicher N,Barad D.Dehydroepiandrosterone(DHEA)supplementation in diminished ovarian reserve(DOR)[J].Reprod Biol Endocrinol,2011,9:67-78.

[18]Barad D,Gleicher N.Effect of dehydroepiandrosterone on oocyte and embryo yields,embryo grade and cell number in IVF[J].Hum Reprod,2006,1(11):2845-2849.

[19]Barad D,Gleicher N.Increased oocyte production'after treatment with dehydroepiandrosterone[J].Fertil Steril,2005,84(3):756.

[20]Narkwichean A,Maalouf W,Bruce Kl,et al.Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve:a meta-analysis[J].Reprod Biol Endocrinol,2013,11:14.

[21]Shoham Z.The clinical therapeutic window for luteinizing hormone in controlled ovarian stiulation[J].Fertfl Steril,2002,77(6):1170-1177.

[22]Fleming R,Rehka P,Deshpande N,et al.Suppression of LH during ovarian stimulation:effects differ in,cycles stimulation with purified urinary FSH and recombinant FSH[J].Hum Reprod,2000,15:1440-1445.

[23]Matormsl B,Prieto B,Expesito A,et al.Mid-follicular LH supplementation in women aged 35-39years undergoing ICSI cycles:a randomized controlled study[J].Reprod Biomed Online,2008,19(6):879-887.

[24]Fabregues F,Iraola F,Casals G,et al.Evaluation of two doses of recombinant human luteinizing hormone supplementation in downregulated women of advanced reproductive age undergoing follicular stimulation for IVF:a randomized clinical study[J].Eur J Obstet Gynecol Reprod Biol,2011,158:56-61.

[25]Mustersl AM,Wely M,Mastenbroek S,et al.The effect of recombinant LH on embryo quality:a randomized controlled trial in women with poor ovarian reserve[J].Hum Reprod,2012,27:244-250.

[26]Surrey ES,Bower J,Hill DM,et al.Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization[J].Fertil Steril,1998,69:419-424.

[27]Griesinger G,Felberbaum R,Diedrich K.GnRH antagonists in ovarian stimulation:a treatment regimen of clinicians’second choice?Data from the German national IVF registry[J].Hum Reprod,2005,20(9):2373-2375.

[28]Homburg R.Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome[J].Best Pract Res Clin Obstet Gynaeeol,2004,18:773-788.

[29]Cheunf LP,Lam PM,Lok IH,et al.GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF:a randomized controlled trial[J].Hum Reprod,2005,20(6):616-621.

[31]Pefinck MJ,Hoek A,Simom AHM,et al.Efficacy of natural cycle IVF:a review of the literature[J].Hum Reprod Update,2002,8(2):129-139.

[32]Blerkom JV,Davis P.Differential effects of repeated ovarian stimulation on cytoplasmic and spindle organization in metaphaseⅡmouse oocytes matured in vito and in vito[J].Hum Repord,2001,16(4):57-764.

[33]黄荷凤,吴琰婷,王婷婷.大剂量促性腺激素超排卵的安全性-负面影响[J].生殖医学杂志,2008,17(6):412-414.

[34]Polinder S,Heijnen EM,Macklon NS,et al.Cost-effectiveness of a mild compared with a standard strategy for lVF:a randomized comparison using cumulative term live birth as the primary endpoint[J].Hum Reprod,2008,23(2):316-323.

[35]DeKlerk C,Macklon NS,Heijnen EM.et al.The psychological impact of IVF fallure after tWO or more cycles of IVF with a mild versus standard treatment strategy[J].Hum Reprod,2007,22(9):2554-2558.

[36]Ata B,Yakin K,Balaban B,et al.Embryo implantation rates in natural and stimulated assisted reproduction treatment cycles in poor responders[J].Reprod Biomed Online,2008,17(2),207-212.

[37]Janssens RM,Lambalk CB,Vermeiden JP,et al.Dosefinding study of triptorelin acetate for prevention of a premature LH surge in IVF:aprospective,randomized,double-blind,placebo-controlled study[J].Hum Reprod,2000,15(11):2333-2340.

[38]Morgia F,Sbracia M,Schimberni M,et al.A controlled trial of netural cycle versus microdose gnadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization[J].Fertil Steril,2004,81(6):1542-1547.

[39]Macklon NS,Fauser BC.Impact of ovarian hyperstimulation on the luteal phase[J].J Reprod Fertil Suppl,2000,55:101-108.

[40]Nargund G.Natural-cycle/mild IVF:a science-based and patient-centered approach for the future[J].Womems Health(Lond Engl),2008,4(4):327-328.

[41]Ma WG,Song H,Das SK,et al.Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation[J].Proc Natl Acad,2003,100(5):2963-2968.

[42]Bersinger NA,Wunder DM,Birkhuser MH,et al.Gene expression In cultured endometrium from women with different outcomes following IVF[J].Mol Hum Repord,2008,14(8):475-484.

[43]Chen J,Liu LL.Effects of electroacupuncture on in vitro fertilization-embryo transfer(IVF-ET)of patients with poor ovarian response[J].Zhongguo Zhen Jiu,2009,29(10):775-779.

[44]滕辉,刘昱磊,王俊玲,等.电针治疗排卵障碍性不孕症疗效观察[J].针灸推拿医学(英文版),2012,10(2):81-84.

[45]Domar AD,Meshay I,Kelliher J,et al.The impact of acupune ture on in vitro fertilization outcome[J].Fertil Steril,2009,91(3):723-726.

[46]So EW,Ng EH,Wong YY,et al.A randomized double blind comparison of real and placebo acupuncture in IVF treatment[J].Hum Reprod,2009,24(2):341-348.